66
Participants
Start Date
April 30, 2014
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Aramchol
PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Placebo
PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Lead Sponsor
Galmed Pharmaceuticals Ltd
INDUSTRY